437 related articles for article (PubMed ID: 30098515)
1. Clinicopathologic features of 300 rhabdomyosarcomas with emphasis upon differential expression of skeletal muscle specific markers in the various subtypes: A single institutional experience.
Rekhi B; Gupta C; Chinnaswamy G; Qureshi S; Vora T; Khanna N; Laskar S
Ann Diagn Pathol; 2018 Oct; 36():50-60. PubMed ID: 30098515
[TBL] [Abstract][Full Text] [Related]
2. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.
Cessna MH; Zhou H; Perkins SL; Tripp SR; Layfield L; Daines C; Coffin CM
Am J Surg Pathol; 2001 Sep; 25(9):1150-7. PubMed ID: 11688574
[TBL] [Abstract][Full Text] [Related]
3. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
4. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience.
Morotti RA; Nicol KK; Parham DM; Teot LA; Moore J; Hayes J; Meyer W; Qualman SJ;
Am J Surg Pathol; 2006 Aug; 30(8):962-8. PubMed ID: 16861966
[TBL] [Abstract][Full Text] [Related]
5. Histopathological, immunohistochemical and molecular cytogenetic analysis of 21 spindle cell/sclerosing rhabdomyosarcomas.
Rekhi B; Singhvi T
APMIS; 2014 Nov; 122(11):1144-52. PubMed ID: 24730567
[TBL] [Abstract][Full Text] [Related]
6. MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.
Rekhi B; Upadhyay P; Ramteke MP; Dutt A
Mod Pathol; 2016 Dec; 29(12):1532-1540. PubMed ID: 27562493
[TBL] [Abstract][Full Text] [Related]
7. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
[TBL] [Abstract][Full Text] [Related]
8. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
[TBL] [Abstract][Full Text] [Related]
9. The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases.
Tsai JW; ChangChien YC; Lee JC; Kao YC; Li WS; Liang CW; Liao IC; Chang YM; Wang JC; Tsao CF; Yu SC; Huang HY
Histopathology; 2019 May; 74(6):933-943. PubMed ID: 30604891
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Myogenin and MyoD1 as Immunohistochemical Markers of Canine Rhabdomyosarcoma.
Tuohy JL; Byer BJ; Royer S; Keller C; Nagai-Singer MA; Regan DP; Seguin B
Vet Pathol; 2021 May; 58(3):516-526. PubMed ID: 33691532
[TBL] [Abstract][Full Text] [Related]
11. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
Yu L; Wang J
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
[TBL] [Abstract][Full Text] [Related]
12. Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.
Michelagnoli MP; Burchill SA; Cullinane C; Selby PJ; Lewis IJ
Med Pediatr Oncol; 2003 Jan; 40(1):1-8. PubMed ID: 12426678
[TBL] [Abstract][Full Text] [Related]
13. Cytomorphology of spindle cell/sclerosing rhabdomyosarcoma, including MYOD1 (LI22R) mutation result.
Rekhi B; Dodd L; Dharavath B; Dutt A
Diagn Cytopathol; 2022 Dec; 50(12):E367-E372. PubMed ID: 35929754
[TBL] [Abstract][Full Text] [Related]
14. Pleomorphic rhabdomyosarcoma in adults: a clinicopathologic study of 38 cases with emphasis on morphologic variants and recent skeletal muscle-specific markers.
Furlong MA; Mentzel T; Fanburg-Smith JC
Mod Pathol; 2001 Jun; 14(6):595-603. PubMed ID: 11406662
[TBL] [Abstract][Full Text] [Related]
15. [Spindle cell/sclerosing rhabdomyosarcoma: a clinicopathological study of 20 cases].
Yang L; Zhang HJ; Yang SJ
Zhonghua Bing Li Xue Za Zhi; 2020 Apr; 49(4):336-342. PubMed ID: 32268670
[No Abstract] [Full Text] [Related]
16. Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.
Krskova L; Augustinakova A; Drahokoupilova E; Sumerauer D; Mudry P; Kodet R
Neoplasma; 2011; 58(5):415-23. PubMed ID: 21744995
[TBL] [Abstract][Full Text] [Related]
17. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood.
Wang NP; Marx J; McNutt MA; Rutledge JC; Gown AM
Am J Pathol; 1995 Dec; 147(6):1799-810. PubMed ID: 7495304
[TBL] [Abstract][Full Text] [Related]
18. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
[TBL] [Abstract][Full Text] [Related]
19. Sclerosing rhabdomyosarcomas in children and adolescents: a clinicopathologic review of 13 cases from the Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group.
Chiles MC; Parham DM; Qualman SJ; Teot LA; Bridge JA; Ullrich F; Barr FG; Meyer WH;
Pediatr Dev Pathol; 2004; 7(6):583-94. PubMed ID: 15630526
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of New Monoclonal Anti-MyoD1 (MX049) for the Diagnosis of Rhabdomyosarcoma: Comparison with 5.8A, EP212, Anti-Desmin, Anti-Myogenin, and Fluorescence
He Y; Chen X; Yu X
Ann Clin Lab Sci; 2020 May; 50(3):412-416. PubMed ID: 32581037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
